Q3 EPS Estimates for Oruka Therapeutics Decreased by Wedbush

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Equities research analysts at Wedbush cut their Q3 2025 earnings per share estimates for Oruka Therapeutics in a research report issued to clients and investors on Tuesday, August 12th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.51) per share for the quarter, down from their prior forecast of ($0.49). Wedbush currently has a “Outperform” rating and a $40.00 price target on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.41) per share. Wedbush also issued estimates for Oruka Therapeutics’ Q4 2025 earnings at ($0.45) EPS, Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.49) EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($2.30) EPS, FY2028 earnings at ($3.05) EPS and FY2029 earnings at ($3.80) EPS.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.02.

Several other analysts have also recently weighed in on the company. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a report on Wednesday, July 23rd. Finally, BTIG Research began coverage on Oruka Therapeutics in a report on Thursday, May 22nd. They set a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $40.38.

Oruka Therapeutics Stock Up 2.5%

Oruka Therapeutics stock opened at $15.37 on Friday. The stock has a market capitalization of $575.61 million, a price-to-earnings ratio of -5.47 and a beta of -0.35. Oruka Therapeutics has a 12-month low of $5.49 and a 12-month high of $52.32. The stock has a 50-day simple moving average of $13.35 and a 200 day simple moving average of $11.53.

Institutional Trading of Oruka Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC bought a new stake in shares of Oruka Therapeutics in the 4th quarter valued at about $343,000. Squarepoint Ops LLC bought a new stake in shares of Oruka Therapeutics in the 4th quarter valued at about $236,000. Millennium Management LLC bought a new stake in shares of Oruka Therapeutics in the 4th quarter valued at about $588,000. Geode Capital Management LLC increased its stake in shares of Oruka Therapeutics by 2,348.6% in the 4th quarter. Geode Capital Management LLC now owns 342,418 shares of the company’s stock valued at $6,643,000 after acquiring an additional 328,434 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new stake in shares of Oruka Therapeutics in the 4th quarter valued at about $54,000. 56.44% of the stock is owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.